CEO Executive AssistantPharma CEO business development time management is, for many pharmaceutical chief executives, the hardest allocation problem in their schedule. Business development is genuinely important. In an industry where internal R&D productivity is under continuous pressure, the ability to in-license assets, forge strategic partnerships, execute out-licensing deals, and pursue M&A at the right moments is a core driver of long-term company value. It also creates an almost unlimited appetite for the CEO’s time, because every counterpart in every BD conversation wants the CEO in the room, on the call, and at the conference.
The discipline required is not reducing CEO involvement in business development. It is making the involvement strategic: present at the moments where the CEO’s authority, relationships, and judgment create value that cannot be replicated at any other organizational level, and absent from the operational machinery that a well-built BD team should own.
The CEO’s Unique Role in Business Development
Before establishing the right time allocation, it is worth being precise about what the CEO contributes to a business development process that a Chief Business Officer or VP of Business Development cannot.
Relationship Capital
The most valuable BD deals, including large in-licensing agreements, transformative partnerships, and strategic M&A, are often unlocked by relationships between CEOs rather than between BD teams. A CEO who has a direct, high-trust relationship with the CEO or CSO of a potential partner company can surface opportunities that never appear in a formal deal flow process. These relationships are built over years, maintained at industry conferences and through direct outreach, and activated at moments of strategic alignment.
This relationship capital is specific to the CEO. It cannot be delegated to the BD team because the counterpart’s CEO will not invest the same relational trust in a VP-level interaction. The implication is that the CEO needs to invest enough time in senior-level relationship maintenance across the industry to build and sustain this capital, even between active deal processes.
Deal Authorization and Strategic Direction
The CEO is the ultimate authority on whether a potential deal fits the company’s strategy, what the company is willing to pay or accept in terms and structure, and when a deal should be prioritized over other competing strategic options. These are not decisions that can be fully delegated.
At the same time, the CEO does not need to be in every negotiation session to exercise this authority. What they need is a clear internal process: defined strategic criteria for what the company is looking for in a deal, clear authorization thresholds for what the BD team can commit to without CEO sign-off, and accessible escalation when those thresholds are reached.
External Credibility
In some deal contexts, particularly those involving large pharma partners considering whether to license from or partner with a smaller company, the CEO’s direct participation signals organizational commitment and strategic seriousness. A counterpart wondering whether a partnership will receive sustained attention from the smaller company’s leadership is reassured by direct CEO engagement. This credibility function is real and should be used deliberately.
When the CEO Should Be in the BD Conversation
A useful framework for pharma CEO business development time management distinguishes between deal stages where CEO presence is high-value and stages where it is low-value or actively counterproductive.
High-Value CEO Involvement
Initial strategic relationship-building deserves CEO investment. A dinner or one-on-one conversation at JPMorgan or BIO with the CEO or CSO of a company that might be a future partner, collaborator, or acquisition target is among the highest-return uses of conference time. These conversations do not need to be transactional; their value is the relational foundation they create for future strategic conversations.
Term sheet negotiation at the principle level is a CEO moment. When the BD team has developed a potential deal to the point where the key economic and strategic terms are being discussed, the CEO’s direct engagement signals commitment and accelerates resolution of the most important terms. This does not mean the CEO negotiates every clause; it means the CEO is accessible and present for the conversations where deal-making decisions are made.
Board-level M&A discussions are inherently CEO-level. Target identification, strategic rationale, price range authorization, and integration strategy are all CEO responsibilities. The M&A process creates significant work for the BD, legal, and finance teams; the CEO’s role is to make the decisions that only they can make and to represent the company in any counterpart CEO relationship that the acquisition requires.
Moments of deal risk or strategic reassessment require CEO judgment. If a late-stage deal is developing in a direction that conflicts with strategic priorities, or if new information about a target or partner creates material uncertainty, the CEO needs to make the call about whether to proceed, restructure, or walk away.
Where CEO Presence Adds Less Value
Deal screening and initial target research is the BD team’s work. Reviewing 30 company profiles to identify five worth pursuing further is not a CEO activity. The BD team should apply the CEO’s defined strategic criteria to the screening process and surface only the shortlisted opportunities.
Due diligence management, beyond defining its scope and reviewing its findings, belongs to the deal team. Scientific diligence is owned by the CMO and clinical team; financial diligence by the CFO and finance team; legal diligence by General Counsel. The CEO receives a synthesized view of diligence findings and makes the go/no-go decision; they do not manage the diligence workstreams.
Routine partnership management for established collaborations (joint steering committee meetings, milestone tracking, communication coordination) is owned by the BD team and the relevant functional leaders. CEO involvement in routine JSC operations adds little value and signals that the company lacks the organizational depth to manage its partnerships independently.
Conference Strategy: JPMorgan, BIO, and Beyond
The January JPMorgan Healthcare Conference and the BIO International Convention are the two most important business development relationship events in the pharmaceutical calendar. Managed poorly, they consume two weeks of CEO time for outcomes that could have been achieved in two days of focused meetings. Managed well, they generate the relationship momentum that powers deal flow for the subsequent 12 months.
Building a Conference Meeting Strategy
A conference without a deliberate meeting strategy defaults to an inbound request queue: the CEO’s schedule fills with whoever was most persistent in requesting time. The result is a calendar full of meetings with counterparts who want something from the CEO, rather than meetings with counterparts whose relationships matter most strategically.
Three to four weeks before a major conference, the CEO and BD team should build a target meeting list based on the company’s strategic priorities for the next 12 months. Which companies are potential partners for the pipeline? Which investors are strategically important to cultivate? Which large pharma business development leaders represent the most important relationships to advance? This list should drive outbound meeting requests, not just inbound acceptance.
The CEO’s conference schedule should include protected time for relationship conversations that are not transactional: dinners, informal gatherings, or one-on-one meetings where the agenda is relationship investment rather than a specific deal. These interactions are where the most valuable long-term connections are made, and they are the first to be sacrificed when the calendar fills with formal business meetings.
CEO Time Allocation at JPM and BIO
A realistic and effective CEO conference allocation at JPMorgan: two to two and a half days, with a maximum of eight to ten substantive meetings per day. Schedules that pack in 15 or 20 meetings per day produce a CEO who is exhausted and unable to be genuinely present for any single interaction. Quality of engagement matters more than volume.
At BIO, where the partnering meeting structure creates a more compressed format, the CEO should be selective about which partnering meetings require personal attendance and which can be managed by the BD team with the CEO available by phone if needed.
The EA’s role in conference preparation is significant: building the preliminary meeting list, coordinating scheduling logistics across dozens of counterparts and time zones, preparing one-page briefing documents for each meeting, and managing the logistical details (travel, accommodations, venue navigation) so the CEO’s mental bandwidth is fully available for the conversations themselves.
Biotech investor time covers the complementary challenge of managing investor relationship time at conferences, which competes directly with BD relationship time during JPM and BIO.
Term Sheet Review: Time Investment and Process Design
Term sheets represent a compressed expression of the most important deal terms, and they deserve careful CEO attention. A CEO who reviews a term sheet superficially because they are time-constrained is making one of the most consequential decisions in the company’s development with inadequate analysis.
Building a Term Sheet Review Process
The CEO is not the only reviewer of a term sheet. The CFO, General Counsel, and relevant scientific or commercial leader (depending on the deal type) should each review from their functional perspective and provide a synthesized recommendation. The CEO’s review then focuses on the strategic judgment: does this deal, at these terms, advance the company’s strategy better than the alternatives (including not doing the deal)?
A structured term sheet review memo from the BD team, covering the key terms, the strategic rationale, the risk factors, and the recommended response, allows the CEO to engage substantively without spending hours on the underlying details. This memo structure is the difference between an hour of high-quality CEO time invested in a term sheet review and a half-day of fragmented time spent piecing together the analysis.
The CEO should set clear expectations with the BD team about the format and depth of term sheet review memos. Teams that present term sheets without structured analysis force the CEO to do analytical work that belongs elsewhere in the organization.
Due Diligence Oversight: Staying Informed Without Managing Execution
Due diligence for a significant in-licensing deal or acquisition can consume enormous organizational resources over four to eight weeks. The CEO needs to remain informed about the diligence findings without absorbing the execution workload that belongs to the deal team.
A weekly 30-minute due diligence status briefing from the deal lead, structured around three questions (what material findings have emerged this week, what decisions are needed from the CEO, and are there any go/no-go signals worth the CEO knowing now), is sufficient to maintain strategic oversight without requiring the CEO to manage the diligence project.
The CEO should define the due diligence scope in advance: which functional areas receive deep diligence (for a biologic in-licensing, CMC and manufacturing are typically critical), which areas receive targeted diligence, and what the deal-breaker criteria are. This upfront definition prevents scope creep and ensures the diligence team knows how to prioritize their time.
According to research published in the Journal of Health Economics, pharmaceutical licensing deals with thorough scientific and commercial due diligence have materially higher rates of commercial success than those where diligence was compressed by deal timing pressure. The CEO who protects adequate due diligence time, even when deal timeline pressure is high, is protecting deal quality.
Protecting Non-BD Strategic Bandwidth
The most significant BD time management risk is not any single deal process. It is the cumulative effect of multiple simultaneous BD conversations on the CEO’s availability for everything else.
Strategic thinking time addresses the broader principle of protecting uninterrupted time for the highest-order strategic thinking that pharmaceutical CEOs must do, regardless of operational demands.
A CEO pursuing three or four active BD processes simultaneously may find that BD has consumed 40 to 50 percent of their strategic bandwidth. Pipeline prioritization decisions, investor relationship development, commercial strategy oversight, and talent management all suffer. The result is a company that is excellent at deal identification but weak at executing against the strategy that should be driving deal selection in the first place.
The practical discipline: a maximum of two active deal processes at any given time that require substantive CEO engagement. When a third process reaches the term sheet stage, the CEO must make an explicit choice about which existing process receives less attention or is paused. This is a resource allocation decision, not a failure of deal ambition.
Conclusion
Pharma CEO business development time management is ultimately a question of strategic clarity. A CEO who knows precisely what the company needs from BD (which therapeutic areas, which deal structures, which partner profiles) can evaluate every potential opportunity against those criteria quickly, engage personally at the moments that matter, and delegate confidently at the moments that do not.
The CEOs who manage BD time most effectively are not those who are always available for every BD conversation. They are those who have built the strategic framework, the BD team capability, and the internal process infrastructure that makes their involvement consistently decisive rather than continuously operational.
Related Reading
For further context, explore How Pharma CEOs Balance Regulatory Affairs and Commercial Time and How Pharma CEOs Manage Time During Major Conference Season.